Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

915 - Cetuximab (Cmab) plus irinotecan (I) versus panitumumab (Pmab) in patients with refractory metastatic colorectal cancer (mCRC) in Ontario


08 Oct 2016


Poster Display


Katarzyna Jerzak


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


K.J. Jerzak, C. Earle, Y. Ko, S. Berry, K.K. Chan

Author affiliations

  • Medicine, Sunnybrook Odette Cancer Center, Sunnybrook HSC, M4N 3M5 - Toronto/CA


Abstract 915


In the BOND trial (Cunningham et al, NEJM 2004) for refractory mCRC, the addition of I to an EGFR antibody improved tumor response rate and time to progression but not overall survival (OS). We assessed the "real world" efficacy and toxicity of combination versus monotherapy in i) all-comers and ii) older patients (pts) who are under-represented in randomized trials.


In Ontario, universal public funding is available for either Cmab + I combination or Pmab monotherapy only in pts with refractory non-mutated Kras mCRC. All pts diagnosed before Dec 2012 and treated with an EGFR antibody for mCRC were identified from the Ontario drug database and linked to the Ontario Cancer Registry and other administrative databases to ascertain baseline characteristics, health services utilization and outcomes. Multivariable Cox and logistic models were constructed to compare the time to treatment discontinuation, overall survival (OS), ED or hospital visits between Cmab + I and Pmab, adjusting for observable confounders (including age, gender, year of diagnosis, stage at presentation, duration of prior treatment in 1st and 2nd line, previous liver resection, rural residence and income quintile) using propensity score methods.


1081 pts were identified (Cmab + I: 278, Pmab: 803); median age: 60 (21.1% >age 70), 36.4% female, 36.2% rectal cancer and 60.1% stage IV at presentation. After adjusting for confounders, the use of Cmab + I as compared to Pmab alone was associated with a prolonged time to treatment discontinuation [median: 3.5 mos vs. 2.8 mos, HR 0.63, 95%CI 0.53-0.75, p 


"Real world" data suggest a possible OS benefit with Cmab + I compared to Pmab alone, without an associated increase in toxicity. Pts age ≥70 appear to experience similar benefit and toxicity from combination therapy. These results suggest a need for adequately powered randomized trials to compare Cmab + I and Pmab like the ongoing ICECREAM study.

Clinical trial identification


Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings